+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05098210

Phase I Study of Personalized Neo-Antigen Peptide Vaccine With Poly ICLC and Nivolumab for Advanced Melanoma, HER2-Negative Breast Cancer, and Non-Small Cell Lung Cancer

Led by Fred Hutchinson Cancer Center · Updated on 2026-07-22

28

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety of a personalized neo-antigen peptide vaccine combined with the Th1 polarizing adjuvant poly ICLC in patients with advanced melanoma, hormone receptor positive HER2 negative metastatic refractory breast cancer, or advanced non-small cell lung cancer. This phase I trial aims to induce a targeted immune response against tumors by using patient-specific neo-antigens. The study is designed to assess tolerability and immune response in these patients with difficult-to-treat cancers. Participants receive poly ICLC either intramuscularly or directly into the tumor once weekly during weeks without vaccine administration. Starting two weeks after poly ICLC begins, they receive the personalized neo-antigen peptide vaccine intramuscularly every four weeks along with intravenous nivolumab every two or four weeks. Treatment lasts 25 weeks if there is no disease progression or unacceptable side effects. Those benefiting may repeat a six-month treatment course. Afterwards, nivolumab monotherapy continues for up to 12 months. Upon progression or stable disease completion, patients may be offered oral ruxolitinib alongside PD-1 inhibitor therapy. During the study, participants undergo tumor biopsies, blood draws, CT or PET scans, and heart function tests like echocardiography or MUGA scans. Follow-up visits occur at 24, 36, and 48 weeks after treatment, with an additional year of monitoring for those continuing nivolumab or off treatment without disease progression. The primary outcome is the incidence of adverse events one year after the first vaccination, with further evaluation of vaccine production, tumor response, and progression-free survival.

CONDITIONS

Brief Title

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Research Team

F

FHCC Intake

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here